Participated · Seed · Sep 2023

Katalys is a commerce media platform operating at the intersection of performance marketing, technology, content and commerce. Its product merges embedded commerce technology with cookieless attribution and a deterministic identity graph to help partners strengthen relationships and drive revenue. For large media companies and digital publishers the platform provides embedded commerce technology proven to boost performance revenue, while e-commerce brands and retailers get scalable product discovery and customer acquisition. The company is based in San Diego, CA. Katalys raised $5.4M in Seed funding with participation from KEY Investment Partners, WGD Capital and GreenAxs Capital. The company intends to use the funds to build additional product features and to support expansion through sales and marketing aimed at the commerce publishing and affiliate marketing industries.

Led · Series B · Jul 2023

Botanica is a Seattle-based company producing cannabis-infused edibles under the Mr. Moxey's and Journeyman brands. Its flagship product, Mr. Moxey's, is a cannabis-infused mint that has sold more than 40 million mints since inception. Journeyman is positioned to lead the small-format drink segment as it expands beyond Washington State. The company raised $9M in a Series B to support growth. Botanica intends to use the funds to expand Mr. Moxey's presence and launch Journeyman Lemonade in Illinois, Colorado and Oregon in 2023. The company is led by Founder and CEO Chris Abbott and President Tim Elliott.

Led · Equity · Aug 2022

FARMACEUTICALRX is a vertically integrated medical marijuana operator focused on premium organic craft products. It cultivates cannabis using a living soil organic method and formulates condition-specific products including live resin vape, solvent-less products, RSO, and edibles. The company markets sub-brands in Ohio such as Burst of Wellness, TreePharm, Local Edibles, CannaRocks, and Open Mind (organic, vegan, gluten-free gummies). FRX holds licenses in Ohio and Pennsylvania and aims to expand reach across demographics at competitive price points. The company expects final organic certification in Q4 2022 and is led by founder and CEO Rebecca Myers alongside a team of scientists, healthcare, organic food and beverage, and cannabis industry professionals. KEY Investment Partners made a $1.5M investment and added a partner to FRX’s board, providing external capital support for the company’s growth plans and potential role in a future Ohio recreational market. FARMACEUTICALRX is one of the largest producers of premium organic medical marijuana products in the U.S. market and operates a vertically integrated platform. The company develops a suite of sub-branded products including Burst of Wellness vape products, TreePharm vape and RSO products, Local Edibles chocolates, and Open Mind organic, vegan, gluten-free gummies. FARMACEUTICALRX is licensed to offer medical marijuana in Pennsylvania and Ohio (combined population >26 million) and operates the FRX Health dispensary in East Liverpool, Ohio. It is expanding by completing a 100,000-square-foot Level 1 cultivation and post-harvest facility in East Liverpool and will bring cultivation and processing methods from its Pennsylvania operations. The company emphasizes R&D-driven product innovation and is led by CEO and founder Rebecca Myers. Recent financing is intended to support the Ohio expansion, equipment purchases, debt repayment, and general working capital as the company pursues revenue and profitability growth.

Participated · Series C · Sep 2021

Flywheel offers an enterprise imaging platform that aggregates, curates, and analyzes medical imaging and video data at scale, helping customers streamline research workflows and prepare AI-ready datasets. During 2025 the company broadened its product suite with a video viewing and annotation tool and launched Flywheel Validated, which supports 21 CFR Part 11–compliant imaging workflows for clinical trials. Its customer roster now includes 10 of the top 20 global pharmaceutical companies and 10 of the top 20 academic medical centers. Commercial traction was strong, with 43 % year-over-year growth in new business, a 40 % increase in committed revenue, and annual recurring revenue from pharma and device customers up 106 %. Net revenue retention exceeded 110 %, underscoring sticky usage and expansion within existing accounts. Backers of the company include Novalis LifeSciences, 8VC, NVIDIA, Microsoft, Novartis, and Intuitive Surgical. The new capital will be used to accelerate product innovation and further penetrate the clinical trial and AI model development markets.

Led · Series B · Jun 2021

Open Book Extracts (OPX) is a Roxboro, North Carolina–based, cGMP-certified manufacturer of plant-based cannabinoid products. Led by CEO Dave Neundorfer and President Oscar Hackett, the company offers one of the largest portfolios of cannabinoid isolates at 99%+ purity, including CBD, CBG, CBN, CBC and THCV. OPX provides formulation services and turnkey finished-goods manufacturing spanning edibles, softgels, tablets, tinctures, pet products and topicals. The company also operates OBX Asia, headquartered in Hong Kong, which provides strategic guidance and on-the-ground support for Asian customers. OPX raised $11.5M in Series B funding through its parent Steady State and plans to use proceeds to accelerate safety studies and efficacy research, build additional scale, and support international distribution opportunities.